Skip to main content

Table 3 Laboratory findings of the Patients by Treatment groups

From: Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial

Laboratory findings All patients (n = 100) Arbidol group (n = 50) KALETRA group (n = 50) P Value
CRP Base, n (%) 100 (100) 50 (100) 50 (100) 0.6
 0, n (%) 16 (16) 7 (14) 9 (18)  
 +, n (%) 29 (29) 15 (30) 14 (28)  
 ++, n (%) 29 (29) 17 (34) 12 (24)  
 +++, n (%) 26 (26) 11 (22) 15 (30)  
CRP 7th day, n (%) 99 (100) 50 (100) 49 (100) 0.2
 0, n (%) 33 (33.3) 17 (34) 16 (32.7)  
 +, n (%) 38 (38.3) 23 (46) 15 (30.6)  
 ++, n (%) 27 (27.2) 10 (20) 17 (34.7)  
 +++, n (%) 1 (2) 0 (0) 1 (2)  
PCR Base, n (%) 100 (100) 50 (50) 50 (50) 0.8
 Positive, n (%) 51 (51) 25 (50) 26 (52)  
PCR Discharge, n (%) 97 (100) 49 (100) 48 (100) 0.2
 Positive, n (%) 18 (38.2) 7 (14.3) 11 (22.9)  
Oxygen Saturation, % (SD)     < 0.001
 In admission 84.9 (8) 85.5 (8.4) 84.3 (7.7) 0.4
 7th day 93 (4.2) 93.9 (3.1) 92 (4.8) 0.02
Erythrocyte Sedimentation Rate, mm/h (SD)     < 0.001
 In admission 40 (19.9) 38.7 (19.7) 41.4 (20.3) 0.5
 7th day 27.8 (17.4) 23.3 (15.5) 32.2 (18.2) 0.01
White-cell count, ×109/L (SD)     < 0.001
 In admission 10.1 (4.9) 10.5 (4.1) 9.8 (5.5) 0.4
 7th day 6.7 (2.2) 6.2 (1.7) 7.2 (2.5) 0.03
Lymphocyte count, × 109/L (SD)     < 0.001
 In admission 20.4 (8.7) 20.3 (8.7) 20.4 (8.9) 0.9
 7th day 26.3 (10.6) 24.7 (8.9) 27.9 (12) 0.1
Neutrophil count, ×109/L (SD)     < 0.001
 In admission 73.8 (11.2) 74.6 (9.7) 73 (12.6) 0.4
 7th day 65.9 (13.2) 69.1 (11.2) 62.7 (14.4) 0.01
Neutrophil/ Lymphocyte ratio (SD)     < 0.001
 In admission 4.7 (3.3) 4.8 (3.7) 4.6 (2.8) 0.7
 7th day 3.4 (3.7) 3.7 (4.3) 3.2 (2.9) 0.4
AST, IU/L (SD)     0.9
 In admission 34.3 (19.9) 33.8 (23.7) 34.7 (15.5) 0.8
 7th day 32.5 (15.2) 31.1 (15.9) 33.8 (14.4) 0.3
ALT, IU/L (SD)     0.1
 In admission 28.8 (16.4) 28.1 (18.2) 29.5 (14.6) 0.6
 7th day 30.2 (15.1) 28.3 (15.6) 32.2 (14.5) 0.2
Total Bilirubin, mg/dL (SD)     0.3
 In admission 0.9 (0.5) 1 (0.5) 0.9 (0.4) 0.3
 7th day 1 (0.4) 1 (0.5) 1 (0.4) 0.8
Serum Creatinine, μmol/L (SD)     0.01
 In admission 1 (0.6) 1.1 (0.8) 0.9 (0.2) 0.1
 7th day 0.9 (0.4) 1 (0.6) 0.9 (0.2) 0.1
Blood Sodium, mEq/L (SD)     < 0.001
 In admission 136.3 (3.7) 136.1 (3.8) 136.4 (3.6) 0.7
 7th day 140.5 (3) 140.7 (2.9) 140.3 (3.1) 0.5
Blood Potassium, mmol/L (SD)     0.08
 In admission 3.9 (0.5) 3.9 (0.5) 3.9 (0.5) 0.9
 7th day 4 (0.5) 3.9 (0.4) 4.2 (0.5) 0.001
TSH, mIU/L (SD)     0.3
 In admission 4.2 (1.8) 4.4 (1.9) 4.1 (1.7) 0.3
 7th day 4.1 (1.8) 4.2 (1.9) 4 (1.7) 0.5
  1. Note: Data are presented as mean (standard deviation) or n (%)
  2. Abbreviation: CRP C-Reactive Protein, PCR Polymerase Chain Reaction, SD Standard Deviation, U/L Units/Liter, mm/h Millimeter/Hour, SGOT Serum Glutamic Oxaloacetic Transaminase, SGPT Serum Glutamic-Pyruvic Transaminase, mg/dl Milligrams per Deciliter, TSH Thyroid Stimulating Hormone
  3. *P-values indicate differences between patients in the Arbidol and the KALETRA groups and between in hospital and 7th day laboratory findings. P < 0.05 was considered statistically significant